Literature DB >> 2669592

Obstructive lung disease after allogeneic marrow transplantation. Clinical presentation and course.

J G Clark1, S W Crawford, D K Madtes, K M Sullivan.   

Abstract

To describe the clinical presentation and progression of obstructive lung disease after marrow transplantation, we examined a sequential sample of 35 patients who had allogeneic marrow transplantation between January 1980 and January 1987, were 16 years or older, had normal pulmonary function tests before transplantation, and developed airflow obstruction defined as FEV1/FVC less than 70% and FEV1 less than 80% predicted 50 days or more after transplantation. Cases were selected from 1029 adult (older than 16 years) patients who underwent allogeneic marrow transplantation during the same period. Patients with airflow obstruction presented with symptoms of cough, dyspnea, or wheezing, or a combination. In 80% the chest radiograph was normal. Airflow obstruction was diagnosed within 1.5 years after transplantation in 33 of 35 patients. Clinical, extensive, chronic graft-versus-host disease was present in 24 patients. Only 4 patients had a complete response to primary therapy of chronic graft-versus-host disease. Serum IgG and IgA levels were decreased in 15 and 25 patients, respectively. The FEV1 declined rapidly (decrease in FEV1 greater than 30% between tests) in 21 patients, but 14 patients with slowly progressive or reversible disease were identified. Mortality was 65% at 3 years after transplant, a significantly higher value (P = 0.016) than the 3-year mortality rate of 44% in a comparison group of 412 concurrent patients with chronic graft-versus-host disease who were 16 years or older, survived more than 80 days after transplantation, and had normal pulmonary function. We concluded that obstructive lung disease after marrow transplantation may be variable with respect to time of onset and rate of progression. Obstructive lung disease was frequently associated with serum immunoglobulin deficiency and clinical, extensive, chronic graft-versus-host disease that was not readily responsive to treatment. Mortality was high but long-term survivors were identified.

Entities:  

Mesh:

Year:  1989        PMID: 2669592     DOI: 10.7326/0003-4819-111-5-368

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  40 in total

Review 1.  How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.

Authors:  Kirsten M Williams
Journal:  Blood       Date:  2016-11-16       Impact factor: 22.113

2.  Bronchial mucoepidermoid carcinoma after allogeneic bone marrow transplantation.

Authors:  J Sánchez; J Serrano; P Gómez; J Román; A Cosano; A Torres
Journal:  J Clin Pathol       Date:  1997-11       Impact factor: 3.411

3.  Pulmonary Clinicopathological Correlation after Allogeneic Hematopoietic Stem Cell Transplantation: An Autopsy Series.

Authors:  Lee Gazourian; Laura Spring; Emily Meserve; David Hwang; Alejandro A Diaz; Samuel Y Ash; Vincent T Ho; Lynette M Sholl; George R Washko
Journal:  Biol Blood Marrow Transplant       Date:  2017-06-28       Impact factor: 5.742

4.  Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation.

Authors:  Kirsten M Williams; Guang-Shing Cheng; Iskra Pusic; Madan Jagasia; Linda Burns; Vincent T Ho; Joseph Pidala; Jeanne Palmer; Laura Johnston; Sebastian Mayer; Jason W Chien; David A Jacobsohn; Steven Z Pavletic; Paul J Martin; Barry E Storer; Yoshihiro Inamoto; Xiaoyu Chai; Mary E D Flowers; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2015-10-22       Impact factor: 5.742

5.  Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease.

Authors:  Yoshihiro Inamoto; Paul J Martin; Barry E Storer; Jeanne Palmer; Daniel J Weisdorf; Joseph Pidala; Mary E D Flowers; Mukta Arora; Madan Jagasia; Sally Arai; Xiaoyu Chai; Steven Z Pavletic; Georgia B Vogelsang; Stephanie J Lee
Journal:  Haematologica       Date:  2014-07-04       Impact factor: 9.941

6.  Improvement of chronic pulmonary graft-vs-host disease manifesting as bronchiolitis obliterans organizing pneumonia following extracorporeal photopheresis.

Authors:  Basak Oyan; Yener Koc; Salih Emri; Emin Kansu
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

7.  Bronchiectasis in bone marrow transplantation.

Authors:  R S Morehead
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

8.  NHANES III equations enhance early detection and mortality prediction of bronchiolitis obliterans syndrome after hematopoietic SCT.

Authors:  K M Williams; O Hnatiuk; S A Mitchell; K Baird; S M Gadalla; S M Steinberg; J Shelhamer; A Carpenter; D Avila; T Taylor; L Grkovic; D Pulanic; L E Comis; B Blacklock-Schuver; R E Gress; S Z Pavletic
Journal:  Bone Marrow Transplant       Date:  2014-01-13       Impact factor: 5.483

9.  Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation.

Authors:  Kirsten M Williams; Jason W Chien; Mark T Gladwin; Steven Z Pavletic
Journal:  JAMA       Date:  2009-07-15       Impact factor: 56.272

10.  Correlation of lung abnormalities on high-resolution CT with clinical graft-versus-host disease after allogeneic versus autologous bone marrow transplantation in children.

Authors:  Laura Merlini; Irene Maria Olivia Borzani; Mehrak Anooshiravani; Isabelle Rochat; Ayse Hulya Ozsahin; Sylviane Hanquinet
Journal:  Pediatr Radiol       Date:  2008-09-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.